Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Vascular endothelial growth factor receptor 2 | ||
Ligand | BDBM139557 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | VEGFR2 Kinase Assay | ||
pH | 7.4±n/a | ||
Temperature | 303.15±n/a K | ||
IC50 | 307±n/a nM | ||
Comments | extracted | ||
Citation | Hull, III, CE; Malone, TC Method of treating conditiions with kinase inhibitors US Patent US9388176 Publication Date 7/12/2016 | ||
More Info.: | Get all data from this article, Assay Method | ||
Vascular endothelial growth factor receptor 2 | |||
Name: | Vascular endothelial growth factor receptor 2 | ||
Synonyms: | CD_antigen=CD309 | FLK1 | Fetal liver kinase 1 (FLK-1) | Flk-1/KDR | KDR | Kinase Insert Domain Receptor | Protein-tyrosine kinase receptor Flk-1 | VEGFR kinase (KDR) | VEGFR-2 | VEGFR-2 (KDR) | VEGFR2 | VGFR2_HUMAN | Vascular Endothelial Growth Factor Receptor Kinase 2 | Vascular endothelial growth factor receptor (VEGFR-2) | Vascular endothelial growth factor receptor 2 (KDR) | Vascular endothelial growth factor receptor 2 (VEGFR-2) | Vascular endothelial growth factor receptor 2 (VEGFR2) | Vascular endothelial growth factor receptor 2 precursor (VEGFR-2) | Vascular endothelial growth factor receptor-2 (VEGFR-2) | ||
Type: | Receptor Tyrosine Kinase | ||
Mol. Mass.: | 151510.97 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P35968 | ||
Residue: | 1356 | ||
Sequence: |
| ||
BDBM139557 | |||
n/a | |||
Name | BDBM139557 | ||
Synonyms: | US8889870, 17 | US9388176, 17 | US9820989, 17 | ||
Type | Small organic molecule | ||
Emp. Form. | C24H33N5O | ||
Mol. Mass. | 407.5517 | ||
SMILES | CC(C)(C)C1CCC(CC1)NC(=O)c1cccc(c1)N1CCc2nc(N)ncc2C1 |(9.34,-.77,;8,-1.54,;8,-3.08,;9.34,-2.31,;6.67,-.77,;5.33,-1.54,;4,-.77,;4,.77,;5.33,1.54,;6.67,.77,;2.67,1.54,;1.33,.77,;1.33,-.77,;,1.54,;,3.08,;-1.33,3.85,;-2.67,3.08,;-2.67,1.54,;-1.33,.77,;-4,.77,;-5.33,1.54,;-6.67,.77,;-6.67,-.77,;-8,-1.54,;-8,-3.08,;-9.34,-3.85,;-6.67,-3.85,;-5.33,-3.08,;-5.33,-1.54,;-4,-.77,)| | ||
Structure |